Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM)

James R. Berenson, MD, Jennifer To, BS, Tanya M. Spektor, PhD, Daisy Martinez, Armando J. Sanchez, MBA, Carley Turner, CCRP, Regina Swift, Benjamin Eades, PharmD, Gary Schwartz, MD, Shahrooz Eshaghian, MD, Laura V. Stampleman, Robert A. Moss, MD, Youram Nassir, MD, Ravindranath Patel, MD, Alberto Bessudo, MD, Daniel Greenwald, MD, Ralph V. Boccia, MD, Stephen Lim, MD, Robert Vescio, MD

Blood (2019) 134 (Supplement_1): 1903.

https://doi.org/10.1182/blood-2019-131370

Published: 2019

Journal Articles

a Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

James Berenson, MD, Laura Stampleman, MD, Alberto Bessudo, MD, Peter J Rosen, MD, Leonard M. Klein, MD, Thomas Woliver, MD, Marshall S. Flam, MD, Shahrooz Eshaghian, MD, Youram Nassir, MD, Swift A Regina, RN, Wang James, Eades Benjamin, PharmD, Tanya M. Spektor, PhD, Robert Vescio, MD

Blood (2015) 126 (23): 5383.

https://doi.org/10.1182/blood.V126.23.5383.5383

Published: 2015

Journal Articles

A Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma

James R. Berenson, MD, Laura V. Stampleman, MD, Alberto Bessudo, MD, Peter J. Rosen, MD, Leonard M Klein, MD, Thomas Woliver, MD, Marshall S. Flam, MD, Shahrooz Eshaghian, MD, Youram Nassir, MD, Regina A. Swift, RN, Robert Vescio, MD

Blood (2014) 124 (21): 4774.

https://doi.org/10.1182/blood.V124.21.4774.4774

Published: 2014

Journal Articles

Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin For Patients With Relapsed/Refractory Multiple Myeloma: Results From a Phase 1/2 Trial

James R. Berenson, MD, James D. Hilger, Ph.D., Leonard Klein, MD, Alberto Bessudo, MD, Peter J. Rosen, MD, Shahrooz Eshaghian, MD, Youram Nassir, MD, Regina A. Swift, RN, Robert Vescio, MD

Blood (2013) 122 (21): 3218.

https://doi.org/10.1182/blood.V122.21.3218.3218

Published: 2013

Journal Articles

A Phase 1/2 Study of Carfilzomib As a Replacement for Bortezomib for Multiple Myeloma (MM) Patients (pts) Refractory to a Bortezomib-Containing Combination Regimen

James R. Berenson, MD, James D. Hilger, Ph.D., Robert Dichmann, MD, Dipti Patel-Donnelly, MD, Ralph V. Boccia, MD, Alberto Bessudo, MD, Laura V. Stampleman, MD, Donald S. Gravenor, MD, Shahrooz Eshaghian, MD, Youram Nassir, MD, Regina A. Swift, RN, Robert Vescio, MD

Blood (2012) 120 (21): 4063.

https://doi.org/10.1182/blood.V120.21.4063.4063

Published: 2012

Journal Articles

A Phase 1/2 Study of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma.

James R. Berenson, MD, James D. Hilger, Ph.D., Leonard M. Klein, MD, Shahrooz Eshaghian, MD, Youram Nassir, MD, Regina A. Swift, RN, Robert Vescio, MD

Blood (2012) 120 (21): 2979.

https://doi.org/10.1182/blood.V120.21.2979.2979

Published: 2012

Journal Articles

A Phase II Study of Pegylated Liposomal Doxorubicin (PLD), Bortezomib, Dexamethasone and Lenalidomide (DVD-R) for Patients with Relapsed/Refractory (R/R) Multiple Myeloma (MM)

James R. Berenson, MD, Ori Yellin, MD, Alan D. Cartmell, MD, Thomas B. S. Woliver, MD, Marshall S. Flam, MD, Youram Nassir, MD, Robert Vescio, MD, Regina A. Swift, RN

Blood (2010) 116 (21): 3044.

https://doi.org/10.1182/blood.V116.21.3044.3044

Published: 2010

Journal Articles

A Randomized Trial Evaluating a New Powered Bone Marrow Aspirate and Core Biopsy System Compared to Traditional Manual Devices.

James R. Berenson, MD, David J. Donahue, Ori Yellin, MD, Gargi Upadhyaya, MD, Youram Nassir, MD, Regina A. Swift

Blood (2009) 114 (22): 4234.

https://doi.org/10.1182/blood.V114.22.4234.4234

Published: 2009

Journal Articles

A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib and Dexamethasone (DVD) for Patients with Previously Untreated Multiple Myeloma (MM).

James R. Berenson, MD, Ori Yellin, MD, Ravi Patel, MD, Chien-Shing Chen, MD, Ralph Vincent Boccia, MD, Donald Colbourn, MD, Honghao (Hank) Yang, MD, PhD, Varun Gupta, MD, George F. Geils, Jr., MD, Youram Nassir, MD, Jacqueline Hilger, MS, Regina A. Swift

Blood (2009) 114 (22): 4936.

https://doi.org/10.1182/blood.V114.22.4936.4936

Published: 2009

Journal Articles

A Phase I Study of Oral Melphalan Combined with LBH589 for Patients with Relapsed or Refractory Multiple Myeloma (MM).

James R. Berenson, MD, Ori Yellin, MD, Ralph V. Boccia, MD, Youram Nassir, MD, Shellie Rothstein, Regina A. Swift

Blood (2009) 114 (22): 1855.

https://doi.org/10.1182/blood.V114.22.1855.1855

Published: 2009

Journal Articles

Factors That Determine Overall Survival among Patients (Pts) with Multiple Myeloma (MM) Treated with Zoledronic Acid (ZOL): Lack of Skeletal-Related Events (SREs) and Occurrence of Osteonecrosis of the Jaw (ONJ) Predict Improved Survival.

James R. Berenson, MD, Ori Yellin, MD, John Crowley, PhD, Herbert Duvivier, MD, Youram Nassir, MD, Regina A. Swift, RN

Blood (2007) 110 (11): 4842.

https://doi.org/10.1182/blood.V110.11.4842.4842

Published: 2007

Journal Articles

Bortezomib, Ascorbic Acid and Melphalan (BAM) Therapy for Patients (pts) with Newly Diagnosed Multiple Myeloma (MM): An Effective and Well-Tolerated Frontline Regimen.

James R. Berenson, MD, Ori Yellin, MD, Donald Woytowitz, MD, Marshall S. Flam, MD, Alan Cartmell, MD, Ravi Patel, MD, Herb Duvivier, MD, Youram Nassir, MD, Regina A. Swift, RN

Blood (2007) 110 (11): 3602.

https://doi.org/10.1182/blood.V110.11.3602.3602

Published: 2007

Journal Articles

Zoledronic Acid (ZOL) Markedly Improves Bone Mineral Density (BMD) for Patients (Pts) with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Bone Loss.

James R. Berenson, MD, Ori Yellin, MD, Ralph V. Boccia, MD, Marshall S. Flam, MD, Siu-Fun Wong, PharmD, Olcay Batuman, MD, Mehdi M. Moezi, MD, Donald Woytowitz, MD, Herb Duvivier, MD, Youram Nassir, MD, Regina A. Swift, RN

Blood (2007) 110 (11): 3606.

https://doi.org/10.1182/blood.V110.11.3606.3606

Published: 2007

NARROW

A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM)

a Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

A Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma

Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin For Patients With Relapsed/Refractory Multiple Myeloma: Results From a Phase 1/2 Trial

A Phase 1/2 Study of Carfilzomib As a Replacement for Bortezomib for Multiple Myeloma (MM) Patients (pts) Refractory to a Bortezomib-Containing Combination Regimen

A Phase 1/2 Study of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma.

A Phase II Study of Pegylated Liposomal Doxorubicin (PLD), Bortezomib, Dexamethasone and Lenalidomide (DVD-R) for Patients with Relapsed/Refractory (R/R) Multiple Myeloma (MM)

A Randomized Trial Evaluating a New Powered Bone Marrow Aspirate and Core Biopsy System Compared to Traditional Manual Devices.

A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib and Dexamethasone (DVD) for Patients with Previously Untreated Multiple Myeloma (MM).

A Phase I Study of Oral Melphalan Combined with LBH589 for Patients with Relapsed or Refractory Multiple Myeloma (MM).

Factors That Determine Overall Survival among Patients (Pts) with Multiple Myeloma (MM) Treated with Zoledronic Acid (ZOL): Lack of Skeletal-Related Events (SREs) and Occurrence of Osteonecrosis of the Jaw (ONJ) Predict Improved Survival.

Bortezomib, Ascorbic Acid and Melphalan (BAM) Therapy for Patients (pts) with Newly Diagnosed Multiple Myeloma (MM): An Effective and Well-Tolerated Frontline Regimen.

Zoledronic Acid (ZOL) Markedly Improves Bone Mineral Density (BMD) for Patients (Pts) with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Bone Loss.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only